real peptides FAQ

MK-677 is the only orally bioavailable GH secretagogue with clinical evidence for body composition changes. Most peptides are degraded by gastric enzymes and require subcutaneous or intramuscular injection. 5-Amino-1MQ and Tesofensine are orally active, but they're metabolic modulators rather than direct GH or IGF-1 elevators. If injections are non-negotiable, your recomposition protocol is limited to MK-677 (for anabolism) plus 5-Amino-1MQ or Tesofensine (for fat oxidation), with the understanding that results will be slower and less dramatic than injectable protocols.

If Viktor Mutt and Said had isolated VIP from brain homogenates rather than intestinal extracts, the peptide's name and initial research trajectory would have been entirely different. The discovery team specifically targeted gut tissue because they were searching for hormones that regulated gastrointestinal secretion. A vasodilatory peptide in neural tissue would have been named and characterized based on its neuromodulatory or neuroprotective effects instead. VIP history would likely have progressed faster toward immunological and neurological applications, because researchers wouldn't have spent fifteen years treating it primarily as a digestive hormone. The peptide's therapeutic development timeline for autoimmune and neurodegenerative conditions might have been accelerated by a decade.

Verify peptide storage conditions and reconstitution timing first—inconsistent results often trace to degraded peptides rather than protocol variability. If one batch was stored at −20°C and another at 4°C prior to reconstitution, potency differences of 15–30% are plausible. Reconstituted peptides lose 5–10% potency per week even under ideal refrigeration; trials separated by weeks using the same reconstituted vial will show declining effect sizes. Aliquot reconstituted peptides into single-use vials immediately after mixing, freeze at −20°C, and thaw only once before administration. Freeze-thaw cycles denature peptides, but a single freeze-thaw from aliquot to administration is acceptable; repeated freeze-thaw of the same vial is not.

Exercise-mimetic research would likely have advanced further before hitting regulatory roadblocks. AICAR's cardiovascular side effects caused such significant setbacks that funding for the entire category dried up for nearly a decade—if SS-LUP-332's tissue-selective approach had been the first proof-of-concept, the field might have maintained momentum through the 2010s. The key lesson from SS-LUP-332 history is that selectivity must be designed into the molecule from the start—retrofitting selectivity onto a non-selective scaffold has never worked.

Start with Thymalin 5–10mg daily for 10 days to restore thymic output. Thymalin directly stimulates thymic epithelial cells, increasing naive T-cell production—the long-term solution for depleted T-cell populations. Follow initial loading with maintenance dosing 2–3 times weekly for 8–12 weeks while monitoring CD4+/CD8+ ratios monthly. Add Thymosin Alpha-1 1.6mg twice weekly if NK cell activity assays show suppression below 15 lytic units—Thymosin Alpha-1 increases NK cytotoxicity 30–50% within 2–4 weeks.

Split the total daily dose into multiple administrations spaced 4–6 hours apart to maintain more consistent plasma levels. For example, a 30mg/kg daily dose could be administered as three 10mg/kg injections at 6-hour intervals rather than a single bolus. This approach reduces peak-to-trough variation and more closely mimics continuous AMPK activation. The tradeoff: increased handling stress in animal models and higher risk of injection-site irritation from frequent punctures. Rotating injection sites (alternating flanks, varying subcutaneous locations) minimizes localized tissue damage. Alternative strategy: some researchers use osmotic minipumps for continuous subcutaneous infusion, eliminating dosing intervals entirely. This requires significantly more reconstituted solution and surgical implantation but provides the most stable pharmacokinetic profile for mechanistic studies.

Discard the vial immediately. Cloudiness or particulate formation indicates protein aggregation or bacterial contamination. Properly reconstituted SS-LUP-332 should remain clear and colorless throughout the 28-day use window when stored at 2–8°C. Aggregation occurs when peptides denature and clump together, rendering them biologically inactive. This can result from repeated temperature cycling, contamination during needle punctures, or exceeding the 28-day stability window. Once aggregation begins, the solution cannot be salvaged. Using aggregated peptide introduces experimental artifacts and invalidates study data. Prevention: minimize vial punctures, use fresh needles for every draw, and maintain consistent refrigerator storage without removing the vial for extended room-temperature periods.

Review your dosing protocol and product source first. Subtherapeutic dosing (below the equivalent of 30 mg/kg/day in preclinical models) will not produce measurable increases in mitochondrial density or oxidative enzyme activity. If you are using a grey-market product without third-party purity verification, the vial may contain significantly less active compound than labeled—or none at all. Even with verified product and correct dosing, individual response variability exists: ERRγ expression levels, baseline mitochondrial density, and genetic polymorphisms in PGC-1α responsiveness influence outcome magnitude. If dosing and product quality are confirmed, lack of response may reflect biological non-responsiveness rather than product failure.

Normal inflammatory markers with persistent symptoms suggest tissue-level inflammation not captured by systemic markers—cytokine imbalances within joints, nervous tissue, or muscle compartments. VIP shows efficacy in localized inflammatory conditions through macrophage reprogramming, reducing tissue inflammation without systemic immunosuppression. Combine with gut barrier restoration protocols (L-glutamine, zinc carnosine, probiotics)—gut permeability perpetuates low-grade inflammation even when serum markers normalize.

Implement sleep hygiene strategies emphasizing consistent sleep-wake timing, morning light exposure, and evening light avoidance. SCN VIP neuron number and VPAC2 receptor expression decline with age in rodent models, correlating with reduced circadian rhythm amplitude, increased sleep fragmentation, and earlier wake times. Aged animals show blunted phase-shifting responses to light and VIP application compared to young controls, suggesting both reduced VIP release and reduced VPAC2 sensitivity contribute to age-related circadian decline. While pharmacological VPAC2 agonists remain investigational, behavioral interventions that strengthen photic input (bright morning light, dim evening environment) maximize residual VIP pathway activation. Scheduled exercise during the active phase provides additional non-photic synchronization through body temperature elevation and hypothalamic activation, partially compensating for declining VIP-mediated synchronization.

Combining SS-LUP-332 exercise gene program activation with structured training produces additive metabolic adaptations in preclinical models. Rodents receiving both SS-LUP-332 and treadmill running protocols showed greater increases in mitochondrial enzyme activity (citrate synthase, cytochrome c oxidase) than either intervention alone—approximately 85–120% above sedentary controls versus 50–60% for training alone or 40–50% for compound alone. This suggests PPARδ activation lowers the training threshold required for mitochondrial remodeling, allowing the same adaptive response at lower exercise volumes. For researchers modeling rehabilitation scenarios or studying populations with exercise intolerance, this synergy indicates SS-LUP-332 may permit meaningful metabolic improvements even when physical activity capacity is severely limited.

Discard it. Lyophilised peptides stored at −20°C can tolerate brief ambient temperature exposure during shipping (24–48 hours), but if the package arrives noticeably warm or without cold packs, the peptide may have undergone partial denaturation. There is no reliable at-home test for potency loss. Visual inspection cannot detect protein unfolding. Research-grade suppliers like Real Peptides ship with temperature monitors and guarantee cold-chain integrity, but if you suspect a breach, contact the supplier immediately rather than proceeding with compromised material.

SS-31 is the most direct intervention. It stabilises cardiolipin on the inner mitochondrial membrane, reducing ROS production at the electron transport chain and improving ATP synthesis efficiency. This matters because impaired mitochondria produce more oxidative stress while generating less energy for detox enzyme function. You'll see improved oxidative stress markers (8-OHdG, MDA) within 6–10 weeks if mitochondrial repair is the limiting factor.

Lyophilised peptides tolerate short-term ambient temperature exposure (up to 25°C for 24–48 hours) without significant degradation, but prolonged heat exposure or multiple temperature cycles compromise structural integrity. If peptides arrive at room temperature but were shipped with cold packs that are still partially frozen, they likely remained within acceptable temperature range. If cold packs are completely thawed and warm to the touch, contact the supplier immediately for replacement. Real Peptides ships all peptides with temperature-monitoring protocols and cold chain packaging designed to maintain −20°C to 2°C throughout transit. Do not attempt to use peptides that have been visibly exposed to heat (discolored powder, oily residue, clumping). Protein denaturation is irreversible and the compound will not retain bioactivity.

VIP has no known adverse interactions with growth hormone secretagogues (MK 677, Ipamorelin), neurotrophic peptides (Cerebrolysin, Dihexa), or thymic peptides (Thymalin). The receptor systems are distinct: VIP acts through VPAC receptors, MK 677 through ghrelin receptors, and Cerebrolysin through neurotrophic pathways. However, combining multiple peptides increases the complexity of tracking individual compound effects and isolating variables. For VIP men over 40 designing multi-peptide research protocols, introduce compounds sequentially (4–6 weeks apart) to establish individual response profiles before layering additional interventions. This approach allows clear attribution of observed effects to specific mechanisms.

Yes. VIP mechanisms operate independently of androgen receptor pathways. Testosterone replacement addresses hormone deficiency but does not modulate immune signaling, circadian rhythm regulation, or neuroprotective pathways controlled by VIP. Research published in Endocrinology found VIP's anti-inflammatory effects persisted regardless of testosterone levels, suggesting complementary rather than overlapping mechanisms. For VIP men over 40 on TRT experiencing persistent inflammation markers (elevated CRP, IL-6) or cognitive decline despite normalized testosterone, VIP research addresses the upstream cellular signaling pathways that hormone replacement doesn't target.

Validate your injury model severity and timing. Peripheral nerves possess intrinsic regenerative capacity. Incomplete crush injuries or short post-injury observation periods may show spontaneous recovery that obscures peptide effects. In rodent sciatic nerve crush models, waiting fewer than 14 days post-injury often yields variable baseline regeneration. Extend observation to 21–28 days and confirm injury completeness via electrophysiology (absence of compound muscle action potentials immediately post-crush). For diabetic neuropathy models, verify sustained hyperglycemia (fasting glucose >250 mg/dL) and document intraepidermal nerve fiber density loss before initiating peptide treatment. Streptozotocin-induced diabetes models require 8–12 weeks to produce measurable neuropathy.

Continue for at least 30 days unless symptoms are severe. Temporary worsening is common as immune cells shift phenotype. As VIP shifts T-cell populations from Th1/Th17 to Treg dominance, there is a transient period (7–21 days) where cytokine release patterns fluctuate, causing temporary fatigue, mild headaches, or increased brain fog. This is mechanistically distinct from the cytokine surge caused by premature VIP. It reflects immune recalibration, not inflammation amplification. The key differentiator: premature VIP worsens symptoms progressively and severely; VIP-induced immune shift causes mild, transient worsening that peaks around day 10–14 and then resolves. If symptoms worsen beyond baseline severity or persist beyond 21 days, retest inflammatory markers (C4a, TGF-beta-1) to rule out missed infection or ongoing biotoxin exposure.

Verify administration timing relative to the subject's endogenous circadian phase. VIP's phase-shifting effect is time-dependent, with maximal effect occurring when administered during the late subjective day (6–10 hours before endogenous melatonin onset). Actigraphy or dim-light melatonin onset (DLMO) testing should confirm baseline circadian phase before initiating VIP protocols. If timing is correct but no shift occurs, consider whether the subject has intrinsic SCN dysfunction (rare but documented in certain neurodegenerative conditions) or whether concurrent light exposure is counteracting the peptide's effect. Bright light exposure in the hours following VIP administration can override peptide-induced phase shifts.

Any temperature excursion above 8°C for lyophilized peptides or above 4°C for reconstituted solutions risks irreversible conformational changes that neither visual inspection nor basic analytical methods detect. SS-31's mitochondrial-targeting depends on precise charge distribution. Heat-induced aggregation or partial deamidation reduces membrane permeability without changing molecular weight on mass spectrometry. If cold chain integrity is uncertain, run a functional assay (cardiomyocyte viability under oxidative stress, receptor binding affinity) before committing to a full protocol. We've reviewed failed replication attempts where the peptide batch was chemically pure but biologically inactive due to shipping mishandling.